Nazivin Sensitive Nasal Spray, 0.05%, 10 ml per bottle.

In stock: 5
$34.56

Ingredients

Active ingredient: oxymetazoline;

1 mL of 0.025% solution contains 0.25 mg of oxymetazoline hydrochloride;

1 mL of 0.05% solution contains 0.5 mg of oxymetazoline hydrochloride;

Excipients: citric acid monohydrate; sodium citrate; glycerin (85%); purified water.

Dosage Form

Nasal spray.

Main physical and chemical properties: an almost transparent solution, ranging from colorless to a slightly yellowish tint.

Pharmacotherapeutic group

Decongestants and other preparations for topical use in diseases of the nasal cavity. Sympathomimetics.

ATC code R01A A05.

Pharmacological properties

Pharmacodynamics.

Nazivin® Sensitive belongs to the group of topical vasoconstrictors. Oxymetazoline exerts sympathomimetic and vasoconstrictive effects, reducing swelling of the nasal mucosa. It constricts blood vessels at the site of application, reduces swelling of the nasal mucosa and upper respiratory tract, and reduces nasal discharge. It restores nasal breathing. Relief of nasal mucosal edema helps restore ventilation of the paranasal sinuses and the middle ear cavity, thereby preventing the development of bacterial complications.

Oxymetazoline has antiviral, anti-inflammatory, immunomodulatory, and antioxidant effects. Thanks to this combined mechanism of action, clinical studies have demonstrated faster and more effective relief of acute rhinitis symptoms (nasal congestion, rhinorrhea, sneezing, and general malaise).

When applied topically to the nose at therapeutic concentrations, it does not irritate the nasal mucosa or cause hyperemia. The half-life is approximately 35 hours after administration. 2.1% of the drug is excreted by the kidneys, and approximately 1.1% is excreted in the feces.

Treatment with 0.05% oxymetazoline nasal spray, compared with saline, significantly reduced the duration of the common cold: on average, from 6 days to 4 days (P < 0.001). In a double-blind, parallel-group comparative study involving 247 adult patients, a faster and more effective reduction in the typical symptoms of acute rhinitis [nasal congestion, runny nose, sneezing, general malaise (P < 0.05)] due to the combination of vasoconstrictive, antiviral, anti-inflammatory, and antioxidant effects of oxymetazoline.

Pharmacokinetics.

The duration of action of the drug is up to 12 hours.

Following intranasal administration, the amount absorbed may sometimes be sufficient to initiate systemic effects, for example, in the central nervous and cardiovascular systems.

No additional data from pharmacokinetic studies in humans are available.

Preclinical safety data

In toxicity studies in dogs involving repeated intranasal administration of oxymetazoline, no safety risks to humans were identified. The results of an in vitro bacterial mutagenicity test were negative. No data on the carcinogenicity of this drug are currently available. No teratogenic effects were observed in rats and rabbits. Doses higher than the therapeutic level were lethal to the embryo or resulted in slowed fetal growth. In rats, suppression of milk production was observed. There were no signs of impaired fertility.

Indications

  • Acute rhinitis.
  • Allergic rhinitis.
  • Episodes of non-infectious vasomotor rhinitis.
  • To restore drainage and nasal breathing in cases of diseases of the paranasal sinuses and eustachitis associated with rhinitis.
  • To reduce swelling prior to diagnostic procedures in the nasal passages.

Contraindications

  • Hypersensitivity to oxymetazoline or any other component of the medication.
  • Atrophic rhinitis.
  • Do not use after transsphenoidal hypophysectomy or other surgical procedures involving exposure of the meninges.
  • Use of monoamine oxidase (MAO) inhibitors and the 2-week period following discontinuation of MAO inhibitor therapy, as well as use of other medications that increase blood pressure.
  • Elevated intraocular pressure, especially in angle-closure glaucoma.
  • Severe forms of cardiovascular disease (e.g., ischemic heart disease) and hypertension.
  • Pheochromocytoma.
  • Metabolic disorders (e.g., hyperthyroidism, diabetes mellitus).
  • Benign prostatic hyperplasia.
  • Porphyria.

Nazivin® Sensitive 0.025% is contraindicated in infants and children under 1 year of age; Nazivin® Sensitive 0.05% is contraindicated in children under 6 years of age.

Interactions with Other Medications and Other Types of Interactions

Concomitant use of oxymetazoline with tranylcypromine-type MAO inhibitors, tricyclic antidepressants, and antihypertensive agents may cause an increase in blood pressure. Therefore, these medications should not be used together.

Special Considerations for Use

Long-term use and overdose of this medication should be avoided. In particular, the effect of nasal decongestants may diminish with prolonged use and overdose (tachyphylaxis). This may necessitate the use of higher doses or more frequent administration, which could lead to the need for continuous use. In case of prolonged use or overdose, treatment with this medication should be discontinued immediately.

If rhinological medications are used improperly, the following effects may occur:

  • reactive hyperemia of the nasal mucosa (rebound effect);
  • chronic swelling of the nasal mucosa (medication-induced rhinitis);
  • atrophy of the nasal mucosa.

Use in cases of chronic rhinitis, as well as at doses higher than recommended, should only occur under a doctor’s supervision.

Use during pregnancy or breastfeeding.

Pregnancy.

Data on the effects of the drug in a limited number of women during the first trimester of pregnancy do not indicate the development of adverse reactions that would affect the course of pregnancy or the health of the fetus or newborn. No other epidemiological data are currently available. Animal studies have shown dose-dependent reproductive toxicity at doses exceeding therapeutic levels. Use this medication with caution during pregnancy, only after consulting a doctor and carefully weighing the risks to the fetus against the benefits to the mother. During pregnancy, the recommended dosage should not be exceeded, as an overdose may impair blood supply to the fetus.

Breastfeeding.

There are no data on the transfer of oxymetazoline into breast milk. This medication should be used during breastfeeding only after consulting a doctor and carefully evaluating the benefit-risk ratio. During breastfeeding, do not exceed the recommended dosage, as an overdose may reduce a woman’s milk supply.

Effect on reaction time when driving or operating machinery.

When used at therapeutic doses, the drug does not affect reaction time while driving or operating machinery. However, a general effect on the cardiovascular and nervous systems cannot be ruled out.

Directions for Use and Dosage

Nazivin® Sensitive nasal spray is intended for intranasal use.

For children aged 1 to 6 years: 1 spray of Nazivin® Sensitive 0.025% into each nostril 2–3 times daily. A single dose should not be administered more than 3 times a day or for longer than 7 days. Do not exceed the recommended dose.

For adults and children aged 6 years and older: 1 spray of Nazivin® Sensitive 0.05% in each nostril 2–3 times a day. A single dose should not be administered more than 3 times a day or for longer than 7 consecutive days. Do not exceed the recommended dose.

The spray mechanism activates when the dispenser is pressed. Before using the spray for the first time, remove the protective cap and press the dispenser periodically to ensure a consistent spray. Hold the bottle under the nostril and spray once. Afterward, clean the dispenser and replace the protective cap.

Children. Nazivin® Sensitive 0.025% is indicated for children aged 1 to 6 years; Nazivin® Sensitive 0.05% is indicated for children aged 6 years and older.

Overdose

After prolonged use or overdose of nasal decongestants, their effectiveness may decrease (tachyphylaxis). This may lead to the need for higher doses or more frequent administration, which could result in the need for continuous use. In case of prolonged use or overdose, treatment with this medication should be discontinued immediately.

Overdose may occur following nasal or accidental oral administration. The clinical picture of imidazole derivative intoxication may be unclear, as periods of stimulation may alternate with periods of depression of the central nervous, cardiovascular, and respiratory systems.

Stimulation of the central nervous system may manifest as anxiety, agitation, hallucinations, and convulsions.

Central nervous system depression may manifest as a decrease in body temperature, lethargy, drowsiness, and the possible development of a coma.

The following symptoms may also occur: miosis, mydriasis, fever, sweating, pallor, cyanosis, palpitations, tachycardia, bradycardia, cardiac arrhythmia, cardiac arrest, hypertension, shock-like hypotension, nausea, vomiting, respiratory failure, and apnea, as well as psychiatric disorders.

In particular, in children, an overdose may primarily cause effects on the central nervous system: convulsions and the development of coma, bradycardia, apnea, as well as hypertension that may progress to hypotension.

Intensive care is indicated in cases of severe overdose. Immediate administration of activated charcoal (an absorbent), sodium sulfate (a laxative), or gastric lavage (in the event of an overdose involving a large amount of the drug) is recommended, since oxymetazoline can be rapidly absorbed.

The use of vasopressor drugs is contraindicated. Non-selective α-blockers may be used as an antidote. If necessary, measures may be taken to lower body temperature, administer anticonvulsant therapy, and provide mechanical ventilation.

Side Effects

Adverse effects are classified by frequency of occurrence into the following categories: very common (≥ 10%), common (≥ 1% and < 10%), uncommon (≥ 0.1% and < 1%), rare (≥ 0.01% and < 0.1%), very rare (< 0.01%), and very rare cases.

Nervous system disorders.

Very rare: restlessness, insomnia, fatigue (drowsiness, sedation), headache, hallucinations (especially in children).

Cardiovascular system.

Rare: palpitations (sensation of a racing heart), tachycardia, hypertension, chest pain.

Very rare: arrhythmias.

Respiratory system.

Common: nasal discomfort (e.g., burning sensation) or dryness of the nasal mucosa, sneezing.

Uncommon: after the effect of Nazivin® Sensitive wears off—a sensation of severe nasal congestion, nosebleeds.

Very rare: apnea in infants and newborns.

Musculoskeletal system.

Very rare: convulsions (especially in children).

Immune system disorders.

Uncommon: hypersensitivity reactions (angioedema, rash, itching).

General disorders and administration site conditions.

Very rare: increased fatigue (drowsiness), weakness.

Frequency unknown: tachyphylaxis (with prolonged use or overdose).

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after the drug’s approval is very important. This allows for continuous monitoring of the benefit-risk profile of the drug. Healthcare professionals are asked to report suspected adverse reactions through the national reporting system.

Shelf life

3 years.

After first opening, use within 12 months.

Storage Conditions

No special storage conditions required. Keep out of reach of children!

Packaging

10 mL or 15 mL of the product per vial; 1 vial per cardboard box.

Dispensing Category

Available without a prescription.